Evoke Pharma, Inc. (NASDAQ:EVOK) Q4 2022 Earnings Call Transcript

Page 2 of 2

David Gonyer: Thanks, Yale.

Operator: Thank you. All right. We have no further questions in the queue. So, this does conclude that portion of today’s call. I would now like to turn the call back over to Dave Gonyer for any additional or closing remarks.

David Gonyer: Great. Thank you. I just wanted to close by saying that our effort to make GIMOTI the standard of care for diabetic gastroparesis got a major boost last year in the areas that we outlined today. I just want to remind everyone that GIMOTI is a novel product still in its launch phase, and such times come with both exhilarating growth and humbling times like the slight decrease in Q4 revenues that we saw though prescriptions were 8% higher. Nonetheless, our trajectory is on a steep positive curve and we look forward to executing on our strategic plan and reporting the results for the remainder of the 2023. Thank you very much for your time.

Operator: Ladies and gentlemen, this concludes today’s Evoke Pharma Fourth Quarter and Full Year 2022 Earnings Call and Webcast. You may disconnect your line at this time, and have a wonderful day.

Follow Evoke Pharma Inc (NASDAQ:EVOK)

Page 2 of 2